27 October 2015 - The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm